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ABSTRACT
Objectives We aimed to review SARS- CoV-2 
seroprevalence studies conducted in Europe to understand 
how they may be used to inform ongoing control strategies 
for COVID-19.
Design Scoping review of peer- reviewed publications and 
manuscripts on preprint servers from January 2020 to 15 
September 2020.
Primary measure Seroprevalence estimate (and lower 
and upper CIs). For studies conducted across a country 
or territory, we used the seroprevalence estimate and 
the upper and lower CIs and compared them to the total 
number of reported infections to calculate the ratio of 
reported to expected infections.
Results We identified 23 population- based 
seroprevalence studies conducted in Europe. Among 12 
general population studies, seroprevalence ranged from 
0.42% among residual clinical samples in Greece to 13.6% 
in an area of high transmission in Gangelt, Germany. Of 
the eight studies in blood donors, seroprevalence ranged 
from 0.91% in North- Western Germany to 23.3% in a 
high- transmission area in Lombardy region, Italy. In three 
studies which recruited individuals through employment, 
seroprevalence ranged from 0.5% among factory workers 
in Frankfurt, Germany, to 10.2% among university 
employees in Milan, Italy. In comparison to nationally 
reported cases, the extent of infection, as derived from 
these seroprevalence estimates, is manyfold higher and 
largely heterogeneous.
Conclusion Exposure to the virus in Europe has not 
reached a level of infection that would prevent further 
circulation of the virus. Effective vaccine candidates are 
urgently required to deliver the level of immunity in the 
population.
INTRODUCTION
With the emergence of a novel pathogen, 
such as SARS- CoV-2—the virus that causes 
COVID-19—initial surveillance focuses 
primarily on those who are hospitalised 
with severe disease and those who report 
symptoms. As a result, early estimates of the 
extent of infection in the population often 
struggle to account for mild or asymptomatic 
infections that do not require medical care. 
This is further exacerbated when availability 
of molecular tests for diagnosis of acute 
infection or capacity for testing is limited. 
This may have been the case in the initial 
stages of the first epidemic peak of COVID-19 
in many countries across Europe. Therefore, 
there is an urgent need for seroprevalence 
studies to enable refined estimates of the 
extent of infection, particularly when used in 
population- based serological surveys.1 2
Understanding the extent of infection 
is important in the current context of the 
COVID-19 pandemic. Many countries in 
Europe were severely impacted by the initial 
epidemic peak in March to June 2020. 
Healthcare facilities were overwhelmed by 
the number of patients requiring hospitalisa-
tion and/or admission to intensive care unit; 
as was public health capacity to (1) identify, 
isolate, test and care for all COVID-19 cases, 
and (2) trace and quarantine contacts of 
known COVID-19 cases. As a result, many 
countries in Europe were forced to imple-
ment blunt public health and social measures 
to break chains of transmission, such as 
nationwide stay at home orders, and the 
closing of borders, workplaces and schools.3
During this time in Europe, a number of 
population- based seroprevalence studies have 
been conducted. As countries have now lifted 
many of the initial broad- reaching measures, 
these studies are important to understand 
Strengths and limitations of this study
 ► Population- based SARS- CoV-2 seroprevalence 
studies have now been conducted in Europe.
 ► We conducted a systematic search of PubMed for 
peer- reviewed publications and MedRxiv/BioRxiv for 
manuscripts on preprint servers from January 2020 
to 15 September 2020.
 ► For studies conducted across a country or territory, 
we used the seroprevalence estimate and the upper 
and lower CIs and compared them to the number of 
reported infections to calculate the ratio of reported 
to expected infections.
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the extent of infection in the population, and to refine 
estimates of disease severity and to enable better under-
standing of population protection against epidemic 
peaks. Nonetheless, population- based seroprevalence 
studies are not without caveats. Notably, the selection of 
participants, and the biases inherent in the selection, as 
well as the performance of the assays used to measure 
antibodies may affect the interpretation of the seroprev-
alence results.4 We provide here a scoping review of the 
population- based seroprevalence studies from Europe 
available as of 15 September 2020 and a synthesis on how 
these results may be used to inform ongoing control strat-
egies for COVID-19.
METHODS
In addition to routine monitoring of population- based 
seroprevalence studies, we conducted a systematic search 
of PubMed for peer- reviewed publications and MedRxiv/
BioRxiv for manuscripts on preprint servers from January 
2020 to 15 September 2020. The search keywords 
included the terms COVID-19, SARS- CoV-2 and seroprev-
alence. The complete search strategy can be found in the 
online supplemental material.
Inclusion criteria
We included publications that met all of the following 
criteria: (1) seroprevalence study conducted in Europe; 
(2) study population derived from the general population 
(rather than a healthcare- based population, or a popula-
tion subject to a specific outbreak investigation); (3) suffi-
cient detail on the type of assay used and the performance 
(specificity and sensitivity) of the assay for detecting 
anti- SARS- CoV-2 antibodies reported in the publication, 
included as a referenced publication, or made publicly 
available by the manufacturer in the case of a commer-
cially available assay; (4) date of sample collection for 
serological testing included; (5) estimate of seroprev-
alence in the population reported as percentage of the 
study population with anti- SARS- CoV-2 IgG antibodies.
Article screening
All identified abstracts were screened in duplicate by 
two reviewers to assess eligibility criteria for inclusion 
in analysis. A third reviewer resolved discrepancies. The 
following data were extracted from each study:
Details of the study: authors, year of publication, 
country, type of publication (publication in peer- 
reviewed journal or manuscript on preprint server).
Methodology: objectives of the study, methods includ-
ing study population, sample size and methods of re-
cruitment, assay used, sensitivity and specificity of the 
assay and how these were determined (reported by 
manufacturer for commercial assays or determined 
as part of the study), as well as the population used to 
determine sensitivity and specificity of the assay.
Outcome: study seroprevalence point estimate (and 
CI, when reported).
While this may lead to an overestimate as to the perfor-
mance of the assay, for commercially available assays, the 
most recently reported specificity and sensitivity data as 
reported by the manufacturer were reported.
Assessment of bias
The Joanna Briggs Institute checklist for studies reporting 
prevalence data was used to identify potential biases. Addi-
tionally, the qualitative categories defined by Bobrovitz et 
al5 were used to determine the magnitude of the biases 
into one of four categories: (1) high: limited certainty 
in prevalence: the true prevalence may be substantially 
different from the estimated prevalence; (2) moderate: 
moderate certainty in the prevalence: the true prevalence 
is likely to be close to the estimate, but there is a possibility 
that it is substantially different; (3) low: high certainty in 
the prevalence estimate: true prevalence is likely close to 
the estimate; and (4) unclear: there was insufficient infor-
mation to assess risk of bias.
Further COVID-19 epidemiological information
We extracted epidemic curve and case counts from the 
European Centre for Disease Prevention and Control 
(ECDC) on 19 September 2020 (https://www. ecdc. 
europa. eu/ en/ publications- data/ download- todays- data- 
geographic- distribution- covid- 19- cases- worldwide) for 
countries/territories in which seroprevalence studies 
included in our analysis were representative of the 
country/territory. Blood sample collection dates were 
overlapped on the epidemic curve to assist with the inter-
pretation of the seroprevalence results.
Comparison of case ascertainment
For the general population studies that were imple-
mented nationwide or across a territory, we used the 
seroprevalence estimate and the upper and lower CIs and 
compared them to the number of reported infections 
15 days before the end of the blood sample collection 
period for the seroprevalence study, based on current 
understanding of anti- SARS- CoV-2 antibody kinetics and 
the ability to detect these antibodies in the second week 
of infection.6 This allowed us to estimate the number of 
infections expected based on the seroprevalence esti-
mate and to calculate the ratio of reported to expected 
infections.
Patient and public involvement
Our study involved the secondary analysis of data and, as 
such, there was no direct patient involvement.
RESULTS
Routine monitoring of literature on SARS- CoV-2 seroprev-
alence, in addition to a systematic search for publications 
on PubMed and the MedRxiv/BioRxiv preprint servers 
identified 315 publications. Of these, 23 met the inclusion 
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criteria and were included in this review (figure 1). Ten 
were published in peer- reviewed journals and 13 were 
manuscripts available on preprint servers (table 1).
Twelve studies7–18 used randomly selected samples from 
the general population, with studies largely conducted 
through household surveys. A further eight studies19–26 
were conducted in populations of blood donors, and three 
additional studies27–29 were conducted among individuals 
who were recruited through employment (table 1).
We did not pool the estimates due to heterogeneity of 
the populations and in dates of sample collection with 
respect to SARS- CoV-2 transmission dynamics. Instead, 
we provide a summary of the seroprevalence estimates 
based on study population (figure 2). In addition, seven 
seroprevalence studies were representative of a country/
territory for which epidemic curve and case counts were 
available from ECDC.7–9 11 12 19 23 Figure 3 demonstrates 
that four studies8 11 19 23 involved blood sample collection 
that included a period of time prior to the first epidemic 
peak, while three were conducted following the first 
epidemic peak, as determined by the epidemic curve.7 9 12
Figure 3 shows the blood sample collection periods 
overlayed on the epidemic curves extracted from the 
European Centre for Disease Prevention and Control.
Population-based seroprevalence studies
Among the 12 studies conducted in the general popu-
lation,7–18 seroprevalence ranged from 0.42% among 
residual clinical samples in Greece7 to 13.6% in an area of 
high transmission in Gangelt, Germany.15 All studies were 
conducted between March and June 2020, with the studies 
conducted May to June reflecting the postepidemic peak 
period in the respective study settings. The largest study 
was a nationwide cross- sectional study conducted in Spain 
in which 51 958 household members were recruited after 
the first epidemic peak in the country and found seroprev-
alence using an immunoassay of 4.6% (95% CI 4.3 to 5.0).9
Three studies8 10 11 performed serial sampling of partici-
pants. In Geneva, Switzerland, participants from an existing 
longitudinal cohort study were sampled across 5 consecu-
tive weeks. While the same individuals were not sampled 
each week, seroprevalence increased: from 4.8% (95% CI 
2.4% to 8.0%, n=341) in the first week to 10.9% (95% CI 
7.9% to 14.4%, n=577) in the third week, before stabilising 
at 10.8% (95% CI 8.2% to 13.9%, n=775) in the fifth week.10
Similarly, in Belgium, residual clinical samples from 
hospitals and diagnostic laboratories were sampled across 
five collection periods from the end of March to the start 
of July. It was estimated that 2.9% (95% CI 2.3% to 3.6%) 
Figure 1 Inclusion of studies in review.
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of the Belgian population had detectable antibodies at 
the end of March, which doubled to 6.0% (95% CI 5.1% 
to 7.1%) 3 weeks later but decreased to 4.5% (95% CI 
3.70% to 5.40%) in the fifth collection period (29 June to 
3 July 2020).10 In Greece, residual clinical samples were 
tested following a geographically stratified sampling plan 
based on regional units. Seroprevalence increased from 
0.24% (95% CI 0.03% to 0.45%) in March to 0.42% (95% 
CI 0.23% to 0.61%) in April.8
Seven of the 12 studies stratified seroprevalence esti-
mates by age.7–11 15 16 In the nationwide seroprevalence 
study conducted in Spain, seroprevalence was found to 
increase with age and the lowest seroprevalence was found 
in those aged 0–19 years, 3.8% (95% CI 3.2% to 4.6%).9 
In Geneva, Switzerland, seroprevalence was 0.8% in 5–9 
years, compared with 9.6% in the 10–19 years and 9.9% in 
20–49 years.10 In Belgium and Greece, age- specific sero-
prevalence from residual clinical samples from hospitals 
and diagnostic laboratories was found to increase with 
age.8 11 In Gangelt, Germany, infection rates were found 
to be lower in the 5–14 years, compared with any other 
age group.15 In Neustadt am Rennsteig, Germany, sero-
prevalence in children and adolescents was found to 
be 1.7%, compared with 9.1% in adults.16 In the Faroe 
Islands,7 although estimates are reported by age, only six 
participants were found to be seropositive so inferences 
as to age- specific seroprevalence are more difficult.
Seroprevalence studies in blood donors
Of the eight studies in blood donor populations,19–26 sero-
prevalence ranged from 0.91% in North- Western Germany 
to 23.3% in the area of Lodi province (Lombardy, Italy) 
where high transmission of COVID-19 was detected from 
the end of February 2020.
One study in Scotland performed serial sampling on 
blood samples collected through blood donation centres. 
All blood samples were negative in mid- March, but rose 
from end of March. Seroprevalence results were stratified 
by location across the country, and seroprevalence was 
found to be heterogeneous by location. In Milan, serial 
sampling of blood donation samples found the seroprev-
alence to increase from 2.0% at the end of February to 
5.0% by mid- March to early April.
While blood donor populations inherently do not 
include children, several adult blood donor popula-
tions were stratified by age. Among 20 640 blood donors 
across Denmark, the youngest (17–29 years: 2.5%) and 
oldest (60–69 years: 2.5%) blood donors were found to 
have higher seroprevalence. In South- East Italy, it was the 
26–35 years old (2.0%) and the 56–65 years old (2.0%) 
age groups which had the highest seroprevalence.
Seroprevalence studies in employees/individuals recruited 
through non-healthcare-related employment
Three studies27–29 recruited individuals through employ-
ment. University employees without any symptoms in 
Milan were found to have a seroprevalence of 10.2%; 
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to have a seroprevalence of 1.3%, while healthy volun-
teer industrial site operators in the metropolitan area of 
Frankfurt am Main were found to have a seroprevalence 
of 0.5%.
Comparison of case underascertainment
We were able to use the serology- derived estimates 
of extent of infection in the four general population 
studies7 9 11 12 that were implemented nationwide or across 
a territory to compare to the total number of reported 
infections reported 15 days prior to the end of the blood 
sample collection period by the country/territory. Across 
the four studies, the ratio of reported to expected number 
ranged from 10% to 63% (table 2).
DISCUSSION
In this scoping review of 23 published seroprevalence 
studies from Europe, we find heterogeneous results, 
ranging from 0.42% among geographically representative 
residual clinical samples across Greece to 23.3% in blood 
donors in an area of high transmission in Lombardy, 
Italy. The studies in which serial sampling was conducted 
noted that an increasing fraction of the population has 
been exposed to the virus. There was no consistency in 
age stratification so inferences as to differences in sero-
prevalence by age are difficult to make at this stage.
In comparison to total reported cases of infection, we 
observed that there was large heterogeneity among coun-
tries in the seroprevalence- derived estimates of extent of 
infection. This likely reflects testing strategies for molec-
ular testing during the first epidemic peak in Europe and 
the laboratory capacity for diagnosing COVID-19, which 
in many places was restricted to those with severe disease 
or those requiring hospitalisation. Understanding testing 
strategies is an important consideration for analysing 
and comparing surveillance data, particularly in the 
COVID-19.
The heterogeneity that we observed in seropreva-
lence estimates across studies may be explained by 
several factors. First, the heterogeneity of transmission 
within Europe and within countries. Across Spain, for 
example, seroprevalence ranged from 1.2% to 14.4%, 
likely reflecting the heterogeneity in transmission inten-
sity across the country.9 Second, the study population and 
the biases inherent in the study design, how the study 
population has been selected in each study, prevent us 
from being able to pool seroprevalence estimates.30 Eight 
studies used blood donor populations, which, by defini-
tion, select adults without any recent symptoms consistent 
Figure 2 Study seroprevalence (point estimate and CI, when reported) (For studies that used serial sampling, the most recent 
seroprevalence estimate was selected).
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with COVID-19. As such, the seroprevalence in blood 
donors is likely to underestimate the seroprevalence of 
the general population, particularly in early seropreva-
lence studies, as is the case in this review.5 In addition, this 
population tends to be healthier than the general popu-
lation.4 The studies among blood donors found sero-
prevalence to be largely comparable to studies that used 
household surveys targeting the general population, as 
shown in table 1, with the exception of the blood donors 
in Lombardy. The 23.3% seroprevalence, measured 
around the peak of transmission in the Lombardy region, 
likely reflects the intensity of transmission at that time.
When considering the lag time between infection and 
measurable antibodies, and the study population, the 
postpeak seroprevalence in the general population may 
be in fact substantially higher. That is, those infected at or 
around the period of most intense transmission (within 
the 2–3 weeks prior to sample collection) would most 
likely have had a negative serological test result but would 
have gone on to seroconvert shortly afterwards.
Further heterogeneity may derive from the type of 
serological assays and the various performance of the 
assays.30 All assays report high sensitivity as shown in 
table 1; however, a context of low seroprevalence, as is 
Figure 3 Blood sample collection periods of studies with respect to reported national epidemic curves of reported cases for 
those studies conducted nationwide/territory- wide (n=7).
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the case for SARS- CoV-2, means low positive predictive 
value for antibody testing. A number of studies report 
the validation of the assay used as part of the study, as 
well as the populations used for this validation. Others 
report the validation performed as part of other studies, 
while others simply report the validation data from the 
manufacturer. A number of studies used the Euroimmun 
ELISA assay,10–12 14–16 20 23 27 yet the performance of the 
assay varies in validation studies, likely due to differences 
in clinical and analytical validity.
A further consideration when interpreting the results of 
the review is the type of the assay used. Only three of the 
23 studies used neutralisation assays,14 21 24 while the rest 
used a rapid immunoassay, an ELISA or chemilumines-
cent immunoassay (CLIA) assay. While the latter detects 
immunoglobulins specific to SARS- CoV-2, often much 
quicker and less laboriously than the former, they do not 
implicitly indicate the strength of an individual’s immune 
response. Neutralisation assays, in contrast, reflect more 
closely the functional role of anti- SARS- CoV-2 antibodies 
in the immune response and therefore give a better indi-
cation as to protection from further infection. Additional 
validation studies are required to understand the correla-
tion between antibody titres detected by a rapid immu-
noassay, ELISA or CLIA, and the neutralising antibody 
response. This is important—for other coronavirus, indi-
viduals who are IgG positive are able to be reinfected,31 32 
and there are now reports of SARS- CoV-2 reinfection.33 
There are several possible explanations for this, including 
the implications related to the detection of antibodies 
versus the detection of neutralising antibodies.
In addition, no longitudinal cohort studies were able 
to be included in this review. As such, all studies present 
antibody responses in individuals at one point in time. For 
the studies that used serial sampling, these were different 
individuals who were sampled, selected from the same 
source population each time. We are therefore unable to 
comment on the duration or persistence of antibodies, 
nor how this may correlate to ongoing protection. Longi-
tudinal studies that follow the same individuals over time 
are needed to understand how long antibody, ideally 
neutralising antibodies, may persist.34 35
Finally, in addition to the humoral response, the body 
also mounts a cellular response against infection. Specif-
ically, T- cells recognise and eliminate other cells infected 
with a virus. By looking only at antibody detection, studies 
to determine the extent of infection in the population, 
the study presupposes that everyone who is infected 
seroconverts, at least to levels that the assay can detect.4 
The proportion of those who mount a cellular response, 
but not a detectable antibody response, is currently 
unclear.36 37 Further research that combines assessment 
of the humoral and cellular responses is needed to under-
stand the correlates of protection and to quantify the 
magnitude of those who may in fact have some protection 
from infection despite a negative antibody result.
Our findings are limited by the quality of the individual 
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to biases. It likely means that the true prevalence may 
be different from that estimated in the study. For this 
reason, we did not pool seroprevalence estimates across 
the region.
Nonetheless, despite this heterogeneity and limitations 
implicit in the various studies, the picture across Europe 
after the first epidemic peak of SARS- CoV-2 is clear: expo-
sure to the virus has been insufficient to deliver the level 
of infection in the population that would be required to 
prevent further circulation of the virus. The threshold 
beyond which such herd immunity may be achieved is 
estimated to be 50%–67%.38 39 Above this threshold, it is 
thought that the virus may no longer be able to circulate 
in the population.
These findings have important policy implications for 
countries in Europe. While a few experts have recom-
mended that countries seek primarily to achieve herd 
immunity by allowing the virus to circulate in societies 
unimpeded, the vast majority of scientists and experts 
have not recommended this strategy.40 This position is 
based on a number of considerations.
First, such a strategy has and will continue to over-
whelm healthcare systems. The devastating effect on the 
healthcare systems was observed early in the pandemic 
in countries which were slow to respond to the identifi-
cation of initial cases. Overwhelmed healthcare systems 
disrupt the delivery of care to patients with COVID-19 
and the delivery of non- COVID-19 health services.41 Elec-
tive surgeries are delayed, vaccine campaigns are halted 
and access to healthcare may be difficult.
Further, we now understand that transmission of 
SARS- CoV-2 is largely concentrated in close- contact 
settings through large droplets, aerosols and contami-
nated surfaces.42 Targeting these high- risk settings for 
control measures will create a large reduction in trans-
mission rates, more so than the blunt public health and 
social measures, and with the advantage of avoiding the 
adverse economic and societal impacts. Further, contact 
tracing and epidemiological studies indicate that a small 
proportion of all people infected likely account for a 
much larger proportion of onward transmission,43–46 
although age- specific rates of contacts also likely influ-
ence transmission and immunity patterns.47
Overall, the results of the initial seroepidemiological 
studies in Europe indicate the population immunity is 
below the likely threshold for herd immunity and that 
measures to (1) identify, isolate, test and care for all 
COVID-19 cases, and (2) trace and quarantine contacts 
of known COVID-19 cases will need to be maintained 
far beyond the emergence of COVID-19 and the initial 
epidemic peak.48 49 In parallel, efficient roll- out of effec-
tive vaccines is needed to deliver the required level of 
herd immunity in the population.
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